After this session, participants should be able to:
- Describe the proposed pathophysiology in multisystem inflammatory syndrome in children (MIS-C) with COVID-19 infection
- Review definition criteria for MIS-C
- Identify key differences between MIS-C and Kawasaki disease (KD)
- Review pharmacotherapy treatment options and considerations for patients with MIS-C utilizing a tier approach
Audience
MD, PharmD, RN
Accreditation
Howard University College of Pharmacy, (COP) is accredited by the Accreditation Council for Pharmacy Education(ACPE) as a provider of continuing pharmacy education. This program meets ACPE criteria for 1 contact hours (0.1 CEU). Credit will be awarded through the CPE Monitor, within 3–4 weeks of the seminar to those who successfully complete the program.
Speakers
Van Tran, PharmD, BCPPS, BCPS, MBA
Clinical Specialist, Neonatal Invensive Care (NICU)
Inova Fairfax Hospital for Children
An Nguyen, PharmD, BCPPS
Clinical Specialist, Pediatric Intensive Care
Inova Fairfax Hospital for Children
For more information about this training, please contact:
Jesse Rung PharmD
Email: dhakrit.rungkitwatt@howard.edu
